Why the study?
Optimal strategies for risk assessment across cardiovascular-kidney-metabolic (CKM) stages needed refinement. Given therapies addressing all 3 CKM axes, novel risk prediction equations incorporating CKM-relevant predictors, outcomes, and social determinants of health were needed to equitably estimate and address risk.
This American Heart Association scientific statement introduces the race-free, sex-specific PREVENT equations to estimate 10- and 30-year total cardiovascular disease risk by incorporating cardiovascular-kidney-metabolic health factors and social determinants of health.
Answers are grounded in this paper and cite their sources.
Supports immediate adoption of PREVENT equations for CVD risk assessment in adults 30-79 years; extends prior models by integrating CKM factors and removing race.
Cardiovascular-kidney-metabolic (CKM) syndrome is a novel construct recently defined by the American Heart Association in response to the high prevalence of metabolic and kidney disease. Epidemiological data demonstrate higher absolute risk of both atherosclerotic cardiovascular disease (CVD) and heart failure as an individual progresses from CKM stage 0 to stage 3, but optimal strategies for risk assessment need to be refined. Absolute risk assessment with the goal to match type and intensity of interventions with predicted risk and expected treatment benefit remains the cornerstone of primary prevention. Given the growing number of therapies in our armamentarium that simultaneously address all 3 CKM axes, novel risk prediction equations are needed that incorporate predictors and outcomes relevant to the CKM context. This should also include social determinants of health, which are key upstream drivers of CVD, to more equitably estimate and address risk. This scientific statement summarizes the background, rationale, and clinical implications for the newly developed sex-specific, race-free risk equations: PREVENT (AHA Predicting Risk of CVD Events). The PREVENT equations enable 10- and 30-year risk estimates for total CVD (composite of atherosclerotic CVD and heart failure), include estimated glomerular filtration rate as a predictor, and adjust for competing risk of non-CVD death among adults 30 to 79 years of age. Additional models accommodate enhanced predictive utility with the addition of CKM factors when clinically indicated for measurement (urine albumin-to-creatinine ratio and hemoglobin A1c) or social determinants of health (social deprivation index) when available. Approaches to implement risk-based prevention using PREVENT across various settings are discussed.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2023) conducted a review in Cardiovascular-kidney-metabolic (CKM) syndrome and primary prevention of total cardiovascular disease. PREVENT (AHA Predicting Risk of CVD Events) risk equations was evaluated on 10- and 30-year total cardiovascular disease (composite of atherosclerotic CVD and heart failure). The sex-specific, race-free PREVENT equations incorporate eGFR and CKM factors to estimate 10- and 30-year risk of total CVD (atherosclerotic CVD and heart failure) in adults aged 30-79 years.
Synapse has enriched 10 related papers. Consider them for comparative context: